Fluidigm Co. (NASDAQ:FLDM) Receives $14.75 Consensus PT from Analysts

Shares of Fluidigm Co. (NASDAQ:FLDM) have been assigned a consensus rating of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.75.

Several brokerages have recently issued reports on FLDM. Piper Jaffray Companies boosted their price objective on Marvell Technology Group from $22.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. BidaskClub cut Westport Fuel Systems from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine cut Welbilt from a “hold” rating to a “sell” rating in a report on Wednesday, June 12th. Finally, Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd.

In related news, insider Levin Easterly Partners Llc sold 83,728 shares of Fluidigm stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $11.50, for a total value of $962,872.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nicolas Barthelemy sold 5,100 shares of Fluidigm stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.43, for a total value of $63,393.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 784,571 shares of company stock valued at $9,449,631. 2.20% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in FLDM. FMR LLC purchased a new position in shares of Fluidigm in the 1st quarter valued at about $24,188,000. RTW Investments LP purchased a new stake in Fluidigm during the 4th quarter worth approximately $7,622,000. ClariVest Asset Management LLC purchased a new stake in Fluidigm during the 1st quarter worth approximately $8,154,000. Millennium Management LLC increased its stake in Fluidigm by 171.1% during the 4th quarter. Millennium Management LLC now owns 932,996 shares of the medical research company’s stock worth $8,042,000 after buying an additional 588,862 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Fluidigm by 57.0% during the 1st quarter. Acadian Asset Management LLC now owns 845,762 shares of the medical research company’s stock worth $11,238,000 after buying an additional 307,013 shares in the last quarter. Hedge funds and other institutional investors own 92.64% of the company’s stock.

Shares of FLDM stock remained flat at $$11.49 on Tuesday. The stock had a trading volume of 439,323 shares, compared to its average volume of 1,014,721. The stock has a market cap of $793.04 million, a PE ratio of -14.36 and a beta of 2.15. The business’s fifty day moving average price is $12.12. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.26 and a quick ratio of 2.86. Fluidigm has a fifty-two week low of $5.50 and a fifty-two week high of $14.90.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.30). The company had revenue of $30.10 million during the quarter, compared to analyst estimates of $29.18 million. Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. Fluidigm’s revenue was up 19.4% on a year-over-year basis. Research analysts forecast that Fluidigm will post -0.5 EPS for the current year.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

See Also: Trading Ex-Dividend Strategy

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.